AbCellera Biologics Inc.
ABCL • NASDAQ
AbCellera Biologics Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Carl Hansen, with a market cap of $991.3M.
CEOCarl Hansen
Next Earnings
Upcoming earnings announcement for AbCellera Biologics Inc.
Date
Thursday, May 7, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.21
Revenue Estimate
$5.7M
Earnings History
Past 12 earnings reports for AbCellera Biologics Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 24, 2026 | Q4 2025 | -$0.03Est: -$0.18 | +83.3% | $44.9MEst: $6.7M | +568.2% |  10-K |
| Nov 6, 2025 | Q3 2025 | -$0.19Est: -$0.17 | -11.8% | $9.0MEst: $6.4M | +38.9% | 10-Q |
| Aug 7, 2025 | Q2 2025 | -$0.12Est: -$0.17 | +29.4% | $17.1MEst: $6.6M | +159.5% | 10-Q |
| May 8, 2025 | Q1 2025 | -$0.15Est: -$0.14 | -7.1% | $4.2MEst: $7.1M | -40.5% | 10-Q |
| Feb 27, 2025 | Q4 2024 | -$0.12Est: -$0.15 | +20.0% | $5.1MEst: $7.6M | -32.7% | 10-K |
| Nov 4, 2024 | Q3 2024 | -$0.17Est: -$0.15 | -13.3% | $6.5MEst: $8.0M | -18.2% | 10-Q |
| Aug 6, 2024 | Q2 2024 | -$0.13Est: -$0.14 | +7.1% | $7.3MEst: $10.2M | -27.9% | 10-Q |
| May 7, 2024 | Q1 2024 | -$0.14Est: -$0.17 | +17.6% | $10.0MEst: $10.8M | -8.2% | 10-Q |
| Feb 20, 2024 | Q4 2023 | -$0.16Est: -$0.13 | -23.1% | $9.2MEst: $8.9M | +3.4% | 10-K |
| Nov 2, 2023 | Q3 2023 | -$0.10Est: -$0.13 | +23.1% | $6.6MEst: $11.9M | -44.5% | — |
| Aug 3, 2023 | Q2 2023 | -$0.11Est: -$0.13 | +15.4% | $10.1MEst: $12.4M | -18.7% | 10-Q |
| May 4, 2023 | Q1 2023 | -$0.14Est: -$0.14 | 0.0% | $12.2MEst: $12.1M | +0.7% | — |